Cover Image
市場調查報告書

全球多發性硬化症 (MS) 治療藥市場:趨勢與預測

Multiple Sclerosis Therapeutics Market, by Drug Class, Route of Administration, Distribution Channel, and Region - Global Trends, and Forecast till 2025

出版商 Coherent Market Insights 商品編碼 629606
出版日期 內容資訊 英文 148 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球多發性硬化症 (MS) 治療藥市場:趨勢與預測 Multiple Sclerosis Therapeutics Market, by Drug Class, Route of Administration, Distribution Channel, and Region - Global Trends, and Forecast till 2025
出版日期: 2018年02月16日 內容資訊: 英文 148 Pages
簡介

本報告提供全球多發性硬化症 (MS) 治療藥市場相關調查分析,提供市場規模與成長率,商機的可能性,推動市場要素·阻礙因素,主要企業等相關的系統性資訊。

第1章 調查目的與前提條件

第2章 市場範圍

第3章 市場動態,法規,趨勢分析

  • 市場動態
  • 法規方案
  • 償付方案
  • 替代療法
  • 開發平台分析
  • 供應鏈分析
  • PEST分析
  • 流行病學

第4章 全球多發性硬化症 (MS) 治療藥市場:藥物各分類

  • 簡介
  • β干擾素
  • 皮質類固醇
  • 單株抗體
  • 抗癌藥物
  • 其他

第5章 全球多發性硬化症 (MS) 治療藥市場:各給藥途徑

  • 簡介
  • 口服
  • 注射

第6章 全球多發性硬化症 (MS) 治療藥市場:各銷售管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 電子商務

第7章 全球多發性硬化症 (MS) 治療藥市場:各地區

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第8章 競爭情形

  • 熱圖分析
  • 市場佔有率分析
  • 企業簡介
    • Novartis AG
    • Teva Pharmaceuticals Industries Ltd.
    • Sanofi S.A.
    • Bayer AG
    • Pfizer, Inc.
    • Biogen Idec
    • Merck & Co., Inc.
    • AbbVie, Inc.
  • 分析師的見解

第9章 章節

目錄

The multiple sclerosis therapeutic agents are intended to promote neurorepair and neuroprotection to prevent disease progression. The disease modifying therapeutics are currently under clinical development to specifically target the disease while avoiding frequent therapeutic administrations. A variety of corticosteroids, immunosuppressants and monoclonal antibodies are approved and recommended to reduce inflammation in multiple sclerosis. The complex nature of disease with its unique individual patient course renders variable clinical outcomes in different patients. Although there is no cure for multiple sclerosis, the currently available therapeutics modify the disease course, accelerate recovery from attacks, and help in managing symptoms.

Market Dynamics

The major factors driving growth of the multiple sclerosis therapeutics market include rise in research and development ultimately leading to the launch of novel drug candidates and the rising prevalence of the condition in children. For instance, in 2014, Plegridy (peginterferon beta-1a) manufactured by Biogen, a disease modifying therapy was approved for the long-term treatment of relapsing forms of multiple sclerosis. According to Multiple Sclerosis Society, approximately five to ten per cent of people with MS experienced their first symptoms before the age of 16. However, the inability of drugs to prevent disease progression and disability, side effects of the approved drugs such as increased risk of infections, flu-like symptoms and progressive multifocal leukoencephalopathy (PML), a viral disease of the brain are the factors hindering market growth.

Key features of the study:

This report provides in-depth analysis of multiple sclerosis therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global multiple sclerosis therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans

Key companies covered as a part of this study include Novartis AG, Teva Pharmaceuticals Industries Ltd., Sanofi Genzyme, Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, market expansion, and marketing tactics

The global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the multiple sclerosis therapeutics market

Detailed Segmentation:

  • Global Multiple Sclerosis Therapeutics Market, By Drug Class:
  • Beta Interferon
  • Corticosteroids
  • Monoclonal Antibodies
  • Antineoplastic Agents
  • Others
  • Global Multiple Sclerosis Therapeutics Market, By Route of Administration:
  • Oral
  • Injection
  • Global Multiple Sclerosis Therapeutics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • Global Multiple Sclerosis Therapeutics Market, By Geography:
  • North America
  • By Drug Class:
  • Beta Interferon
  • Corticosteroids
  • Monoclonal Antibodies
  • Antineoplastic Agents
  • Others
  • By Route of Administration:
  • Oral
  • Injection
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • U.S.
  • Canada
  • Latin America
  • By Drug Class:
  • Beta Interferon
  • Corticosteroids
  • Monoclonal Antibodies
  • Antineoplastic Agents
  • Others
  • By Route of Administration:
  • Oral
  • Injection
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Drug Class:
  • Beta Interferon
  • Corticosteroids
  • Monoclonal Antibodies
  • Antineoplastic Agents
  • Others
  • By Route of Administration:
  • Oral
  • Injection
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug Class:
  • Beta Interferon
  • Corticosteroids
  • Monoclonal Antibodies
  • Antineoplastic Agents
  • Others
  • By Route of Administration:
  • Oral
  • Injection
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Drug Class:
  • Beta Interferon
  • Corticosteroids
  • Monoclonal Antibodies
  • Antineoplastic Agents
  • Others
  • By Route of Administration:
  • Oral
  • Injection
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Drug Class:
  • Beta Interferon
  • Corticosteroids
  • Monoclonal Antibodies
  • Antineoplastic Agents
  • Others
  • By Route of Administration:
  • Oral
  • Injection
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Novartis AG*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Teva Pharmaceuticals Industries Ltd.
  • Sanofi S.A.
  • Bayer AG
  • Pfizer, Inc.
  • Biogen Idec
  • Merck & Co., Inc.
  • AbbVie, Inc.
  •  “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Market Trends
  • Regulatory Scenario
  • Reimbursement Scenario
  • Alternative Therapies
  • Pipeline Analysis
  • Supply Chain Analysis
  • PEST Analysis
  • Epidemiology

4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017 - 2025
    • Segment Trends
  • Beta Interferon
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Monoclonal Antibodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Antineoplastic Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)

5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017 - 2025
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)

6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017 - 2025
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • E-Commerce
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)

7. Global Multiple Sclerosis Therapeutics Market, By Region, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2025
  • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of APAC
  • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis (3x3 Matrix)
  • Company Profiles
    • Novartis AG*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Teva Pharmaceuticals Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Bayer AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Biogen Idec
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • AbbVie, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact

Browse 35 market data tables and 40 figures on "Multiple Sclerosis Therapeutics Market - Global forecast to 2025".

Back to Top